SCHEMBL21361611

SCHEMBL21361611

COc1cc(F)ccc1N1CCN(S(=O)(=O)N2CCCN([C@@H](C)C3CCCCC3)CCCN(S(=O)(=O)c3ccc(N(C)C)cc3)C[C@H](C)C2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
GFER P55789 2/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
GAA P10253 4/20 0.37
TP53 P04637 3/20 0.36
LMNA P02545 3/20 0.36
HTT P42858 2/20 0.36
POLB P06746 1/20 0.35
TSHR P16473 3/20 0.35
USP2 O75604 1/20 0.35
GLA P06280 1/20 0.35
MAPK1 P28482 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MAPT P10636 2/20 0.35
RECQL P46063 1/20 0.35
PKM P14618 1/20 0.35
DRD2 P14416 1/20 0.34
ADRA1D P25100 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21361419 0.92 SMN1; SMN2 (0.40) ALDH1A1SMN1; SMN2KMT2AGAAPOLB
SCHEMBL25435310 0.92 SMN1; SMN2 (0.40) ALDH1A1SMN1; SMN2KMT2AGAAPOLB
SCHEMBL21361616 0.86 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2GFERKMT2AMEN1
SCHEMBL21361542 0.81 SMN1; SMN2 (0.43) ALDH1A1SMN1; SMN2GFERKMT2AMEN1
SCHEMBL21361539 0.78 SMN1; SMN2 (0.40) ALDH1A1SMN1; SMN2POLBTSHR
SCHEMBL23102067 0.77 ALDH1A1 (0.46) ALDH1A1GFERKMT2AGAATP53
SCHEMBL26239411 0.77 GPR6 (0.31) DRD2ADRA1DADRA1AADRA1B
SCHEMBL21361487 0.77 LMNA (0.43) ALDH1A1SMN1; SMN2KMT2AMEN1GAA
SCHEMBL21361409 0.77 SMN1; SMN2 (0.45) SMN1; SMN2KMT2AGAATP53LMNA
SCHEMBL21361519 0.76 ALDH1A1 (0.34) ALDH1A1SMN1; SMN2GFERKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2023-02-14 US disclosed
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-12-22 US disclosed
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2021-03-18 US disclosed
WO-2019178510-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2019-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors SEC61B, SEC61A1, SEC61G ALDH1A1 4848/4885SMN1; SMN2 4582/4885GFER 3876/4885
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G ALDH1A1 4834/4885SMN1; SMN2 4499/4885GFER 3928/4885
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G ALDH1A1 4817/4885SMN1; SMN2 4421/4885GFER 3590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.